Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID W/ COLCHICINE vs PROBALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.
Inhibits xanthine oxidase, reducing uric acid production.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Gout,Hyperuricemia,Prevention of tumor lysis syndrome
1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.
500 mg orally once daily.
Probenecid: 5-8 hours (terminal half-life, prolonged in renal impairment); Colchicine: 26-31 hours (mean terminal half-life in adults, can be extended in elderly or renal/hepatic impairment).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (Cr Cl <30 m L/min) requiring dose adjustment.
Probenecid: Hepatic via glucuronidation, oxidation; inhibits renal tubular secretion of many drugs. Colchicine: Hepatic via CYP3A4 and P-glycoprotein (P-gp); undergoes enterohepatic recirculation.
Primarily hepatic via CYP450; produces active metabolites.
Probenecid: Renal (70-80% as unchanged drug and metabolites, primarily via tubular secretion); Colchicine: Hepatic metabolism (approx. 80%) and renal excretion (10-20% unchanged). Fecal excretion of metabolites accounts for a minor fraction.
Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for 15-25% with the remainder as metabolites.
Probenecid: 85-95% bound to plasma albumin; Colchicine: 39-44% bound to albumin and alpha1-acid glycoprotein.
90-95% bound primarily to albumin and alpha-1-acid glycoprotein.
Probenecid: 0.15-0.2 L/kg (highly confined to plasma and extracellular fluid); Colchicine: 2-5 L/kg (extensive tissue distribution, particularly in leukocytes and liver).
0.15-0.25 L/kg; reflects distribution mainly into extracellular fluid with limited tissue penetration.
Probenecid: Oral bioavailability approximately 100% (well absorbed, but first-pass metabolism reduces systemic exposure to parent drug); Colchicine: Oral bioavailability 24-45% (subject to first-pass metabolism and transport by P-glycoprotein).
Oral: 75-85% (first-pass metabolism reduces absolute bioavailability); Intravenous: 100%.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min, reduce dose to 1 tablet once daily; for GFR > 50 m L/min, no adjustment needed.
Cr Cl 30-50 m L/min: 250 mg daily; Cr Cl <30 m L/min: 125 mg daily; hemodialysis: 125 mg after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce colchicine dose by 50% (use combination product cautiously); Child-Pugh C: contraindicated due to colchicine toxicity risk.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: not recommended.
Not recommended for pediatric use; safety and efficacy not established.
10 mg/kg orally once daily, max 500 mg; for children <2 years: 5 mg/kg once daily.
Start with 1 tablet once daily; monitor renal function and colchicine toxicity due to age-related decline in GFR and increased sensitivity.
Start at 250 mg daily; monitor renal function and adjust based on Cr Cl.
Colchicine can cause fatal toxicity if not dosed correctly; fatalities have occurred with doses as low as 0.8 mg in patients with renal or hepatic impairment, or in combination with P-glycoprotein or CYP3A4 inhibitors.
None
Blood dyscrasias (aplastic anemia, agranulocytosis), hepatotoxicity, neuromuscular toxicity, renal impairment, drug interactions with P-gp and CYP3A4 inhibitors, use with caution in elderly and debilitated patients.
Acute gout flares may occur initially,Hypersensitivity reactions including Stevens-Johnson syndrome,Renal impairment requires dose adjustment
Hypersensitivity to probenecid or colchicine, concurrent use of P-gp or strong CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine, ketoconazole), severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, pre-existing blood dyscrasias.
Hypersensitivity to probalan,Concurrent use with azathioprine or mercaptopurine
Avoid high-purine foods (organ meats, shellfish, red meat, beer) as they increase uric acid and reduce drug efficacy. Alcohol, especially beer, contraindicated. Acidic foods (cranberries, citrus) may increase colchicine absorption; limit large amounts. Grapefruit may increase colchicine levels; avoid.
High-purine foods (organ meats, anchovies, sardines) may increase uric acid; limit intake. Alcohol, especially beer, reduces uricosuric effect and increases uric acid; avoid or limit. Aspirin (anti-inflammatory doses) and some diuretics (thiazides) can reduce efficacy; avoid concurrent use.
Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in animals. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use only if clearly needed.
PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with third-trimester exposure due to inhibition of fetal renal clearance. Risk cannot be excluded; use only if maternal benefit outweighs potential fetal risk.
Colchicine: limited excretion into breast milk; M/P ratio ~0.4; low relative infant dose (~5% maternal weight-adjusted dose). Probenecid: excreted in milk but no adverse reports. Consider alternative if infant <3 months or G6PD deficiency.
Probenecid is excreted into breast milk in small amounts. M/P ratio is approximately 0.1. Infant exposure is negligible, but caution is advised due to potential for kernicterus in jaundiced infants. Consider discontinuing breastfeeding if infant is G6PD deficient.
No specific dose adjustments required; however, increased glomerular filtration rate in pregnancy may reduce probenecid efficacy; colchicine clearance unchanged. Monitor clinical response and titrate dose if needed.
No standard dose adjustment recommended. Pregnancy increases renal clearance and volume of distribution, potentially reducing serum concentrations. Consider therapeutic drug monitoring if response inadequate. Avoid use in third trimester unless benefits outweigh risks.
Probenecid reduces renal excretion of colchicine, increasing colchicine toxicity risk; dose adjustment required. Contraindicated in G6PD deficiency and blood dyscrasias. Monitor CBC and renal function. Use with caution in patients with peptic ulcer disease (probenecid may exacerbate). Colchicine neuromyopathy risk increases with concurrent statins or cyclosporine.
PROBALAN (probenecid) is a uricosuric agent used for chronic gout. Monitor serum uric acid levels; goal <6 mg/d L. Avoid in patients with creatinine clearance <50 m L/min or history of uric acid stones. Ensure adequate hydration (≥2 L/day) to prevent nephrolithiasis. Alkalinize urine (p H 6.5-7.0) with potassium citrate if needed. Contraindicated with aspirin >1 g/day due to decreased uricosuric effect. Not effective during acute gout attacks; initiate after inflammation subsides.
Take with food or milk to reduce GI upset.,Drink plenty of fluids (2-3 L/day) to prevent kidney stones and help urate excretion.,Avoid alcohol, as it can increase uric acid levels and precipitate gout attacks.,Stop at first signs of infection, sore throat, or easy bruising (myelosuppression).,Report muscle pain or weakness (colchicine myopathy), especially if on statins.,Do not exceed prescribed dose; colchicine overdose can be fatal.,May cause gout flares initially; continue medication and contact provider if flares persist.
Take with food or milk to reduce gastrointestinal upset.,Drink at least 2 liters of water daily to prevent kidney stones.,Avoid aspirin or aspirin-containing products; use acetaminophen for pain.,Report rash, fever, or painful urination immediately.,May take several months to achieve full effect; do not stop suddenly.
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID W/ COLCHICINE vs PROBALAN, answered by our medical review team.
PROBENECID W/ COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion. Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis.. PROBALAN is a Uricosuric Agent that works by Inhibits xanthine oxidase, reducing uric acid production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID W/ COLCHICINE and PROBALAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID W/ COLCHICINE is: 1 tablet (500 mg probenecid / 0.5 mg colchicine) orally twice daily, with or without food.. The standard adult dose of PROBALAN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID W/ COLCHICINE and PROBALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID W/ COLCHICINE is classified as Category A/B. Risk cannot be ruled out. Colchicine is associated with chromosomal abnormalities and fetal harm at high doses in animal studies; human data limited. Probenecid not teratogenic in . PROBALAN is classified as Category C. PROBALAN (probenecid) is not associated with major congenital malformations in human studies. However, dose-dependent neonatal toxicity (lactic acidosis) has been reported with thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.